AR004512A1 - Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados - Google Patents
Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivadosInfo
- Publication number
- AR004512A1 AR004512A1 ARP960104355A AR10435596A AR004512A1 AR 004512 A1 AR004512 A1 AR 004512A1 AR P960104355 A ARP960104355 A AR P960104355A AR 10435596 A AR10435596 A AR 10435596A AR 004512 A1 AR004512 A1 AR 004512A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- procedure
- preparation
- carry out
- benzotiazolone
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- BXQNSPXDWSNUKE-UHFFFAOYSA-N 1,3-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)C=NC2=C1 BXQNSPXDWSNUKE-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Derivados de benzotiazolona de la fórmula I, que incluye los isómeros ópticos del mismo en el cual X representa-SO2NH- o -NHSO2-,p, q, y, rindependientemente representan 2 ó 3 , Y representa tienilo optativamente sustituido por alquilo oh alógeno, o feniltio-o fenilo optativamente sustituídopor alquilo o halógeno, y cada R presenta, independientemente, H o alquilo, y sales, ésteres y amidas farmacéuticamente aceptables del mismo. Se describeademás un procedimiento para supreparació n, un compuesto intermediario útil para llevar a cabo dicho procedimiento y una composición farmacéutica quecomprende dichos derivados. Los compuestos son agonistas del receptor de la dopamina DA2 y agonistas del adrenorreceptor B2y están ind icados paraenfermedades obstructivas de las vías aéreas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9518952.8A GB9518952D0 (en) | 1995-09-15 | 1995-09-15 | Compounds |
| GBGB9614346.6A GB9614346D0 (en) | 1996-07-10 | 1996-07-10 | Benzothiazolone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004512A1 true AR004512A1 (es) | 1998-12-16 |
Family
ID=26307771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104355A AR004512A1 (es) | 1995-09-15 | 1996-09-13 | Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US5846989A (es) |
| EP (1) | EP0850232B1 (es) |
| JP (1) | JP3213327B2 (es) |
| KR (1) | KR19990044674A (es) |
| CN (2) | CN1073098C (es) |
| AR (1) | AR004512A1 (es) |
| AT (1) | ATE190610T1 (es) |
| AU (1) | AU706094B2 (es) |
| BR (1) | BR9610316A (es) |
| CA (1) | CA2231003A1 (es) |
| CY (1) | CY2227B1 (es) |
| CZ (1) | CZ74098A3 (es) |
| DE (1) | DE69607183T2 (es) |
| EE (1) | EE03395B1 (es) |
| ES (1) | ES2146901T3 (es) |
| GR (1) | GR3033681T3 (es) |
| HU (1) | HUP9802393A3 (es) |
| IL (4) | IL141954A0 (es) |
| IS (1) | IS4679A (es) |
| MY (1) | MY113518A (es) |
| NO (1) | NO310721B1 (es) |
| NZ (4) | NZ318007A (es) |
| PL (1) | PL325517A1 (es) |
| PT (1) | PT850232E (es) |
| SK (1) | SK282394B6 (es) |
| TR (1) | TR199800457T2 (es) |
| TW (1) | TW356468B (es) |
| WO (1) | WO1997010227A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1498124T3 (da) * | 1997-10-17 | 2007-11-05 | Ark Therapeutics Ltd | Anvendelse af inhibitorer i renin-angiotensinsystemet |
| SE0004750D0 (sv) * | 2000-12-19 | 2000-12-19 | Astrazeneca Ab | Novel formulation |
| GB0218629D0 (en) * | 2002-08-09 | 2002-09-18 | Novartis Ag | Organic compounds |
| AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| CN100569760C (zh) | 2003-11-21 | 2009-12-16 | 施万制药 | 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物 |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| UA94235C2 (en) * | 2005-08-09 | 2011-04-26 | Астразенека Аб | Novel benzothiazolone derivatives |
| RU2415136C2 (ru) * | 2005-08-09 | 2011-03-27 | Астразенека Аб | Новые производные бензотиазолона |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200740781A (en) * | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP2094646A1 (en) * | 2006-12-20 | 2009-09-02 | AstraZeneca AB | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| UY31905A (es) | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
| RU2011101664A (ru) * | 2008-06-20 | 2012-07-27 | Астразенека Аб (Se) | Фармацевтическая композиция, содержащая 4-гидрокси-2-оксо-2, 3-дигидро-1, 3-бензотиазол-7-ильное соединение, для модулирования активности бета2- адренорецепторов |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314944A (en) * | 1980-08-22 | 1982-02-09 | Smithkline Corporation | 4-Aminoalkyl-7-hydroxy-2(3H)-indolones |
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| GB8426200D0 (en) * | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
| US4554284A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
| US4554287A (en) * | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
| DK514585A (da) * | 1984-11-08 | 1986-05-09 | Syntex Inc | Aminoethylanilinderivater |
| DE3728695A1 (de) * | 1987-08-25 | 1989-03-09 | Schering Ag | Neue benzimidazol-derivate |
| GB9024208D0 (en) * | 1990-11-07 | 1990-12-19 | Salutar Inc | Compounds |
| GB9210632D0 (en) * | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| GB9211172D0 (en) * | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
| IE914003A1 (en) * | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
-
1996
- 1996-09-11 TW TW085111075A patent/TW356468B/zh active
- 1996-09-12 US US08/776,770 patent/US5846989A/en not_active Expired - Lifetime
- 1996-09-12 BR BR9610316A patent/BR9610316A/pt not_active Application Discontinuation
- 1996-09-12 TR TR1998/00457T patent/TR199800457T2/xx unknown
- 1996-09-12 PL PL96325517A patent/PL325517A1/xx unknown
- 1996-09-12 WO PCT/GB1996/002247 patent/WO1997010227A1/en not_active Ceased
- 1996-09-12 CN CN96198311A patent/CN1073098C/zh not_active Expired - Fee Related
- 1996-09-12 EP EP96930256A patent/EP0850232B1/en not_active Expired - Lifetime
- 1996-09-12 AT AT96930256T patent/ATE190610T1/de not_active IP Right Cessation
- 1996-09-12 KR KR1019980701929A patent/KR19990044674A/ko not_active Ceased
- 1996-09-12 HU HU9802393A patent/HUP9802393A3/hu unknown
- 1996-09-12 NZ NZ318007A patent/NZ318007A/xx unknown
- 1996-09-12 IL IL141954??A patent/IL141954A0/xx unknown
- 1996-09-12 SK SK295-98A patent/SK282394B6/sk unknown
- 1996-09-12 AU AU69371/96A patent/AU706094B2/en not_active Ceased
- 1996-09-12 CA CA002231003A patent/CA2231003A1/en not_active Abandoned
- 1996-09-12 CZ CZ98740A patent/CZ74098A3/cs unknown
- 1996-09-12 EE EE9800069A patent/EE03395B1/xx not_active IP Right Cessation
- 1996-09-12 IL IL12363996A patent/IL123639A/en not_active IP Right Cessation
- 1996-09-12 IL IL14195596A patent/IL141955A0/xx unknown
- 1996-09-12 PT PT96930256T patent/PT850232E/pt unknown
- 1996-09-12 JP JP51175297A patent/JP3213327B2/ja not_active Expired - Fee Related
- 1996-09-12 IL IL14195696A patent/IL141956A0/xx unknown
- 1996-09-12 DE DE69607183T patent/DE69607183T2/de not_active Expired - Fee Related
- 1996-09-12 ES ES96930256T patent/ES2146901T3/es not_active Expired - Lifetime
- 1996-09-13 MY MYPI96003788A patent/MY113518A/en unknown
- 1996-09-13 AR ARP960104355A patent/AR004512A1/es not_active Application Discontinuation
-
1998
- 1998-03-04 IS IS4679A patent/IS4679A/is unknown
- 1998-03-12 NO NO19981104A patent/NO310721B1/no unknown
- 1998-09-02 US US09/146,047 patent/US6008365A/en not_active Expired - Lifetime
- 1998-09-02 US US09/146,046 patent/US5977384A/en not_active Expired - Lifetime
- 1998-09-02 US US09/146,048 patent/US6080869A/en not_active Expired - Lifetime
- 1998-09-02 US US09/145,281 patent/US5973167A/en not_active Expired - Lifetime
- 1998-10-19 NZ NZ332395A patent/NZ332395A/xx unknown
- 1998-10-19 NZ NZ332397A patent/NZ332397A/xx unknown
- 1998-10-19 NZ NZ332396A patent/NZ332396A/xx unknown
-
2000
- 2000-06-14 GR GR20000401368T patent/GR3033681T3/el not_active IP Right Cessation
- 2000-12-30 CN CN00137051A patent/CN1356323A/zh active Pending
-
2001
- 2001-07-20 CY CY0100016A patent/CY2227B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004512A1 (es) | Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| UY26782A1 (es) | Derivados del benzotiazol | |
| UY28339A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| PA8452001A1 (es) | Derivados de macrolidos c-4" sustituidos | |
| NO20071490L (no) | Farmasoytisk aktive isoindolderivater | |
| CR7743A (es) | Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf) | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| ES2213732T3 (es) | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. | |
| AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
| MX9304524A (es) | Nuevos derivados de indol y composiciones que los contienen. | |
| AR014747A1 (es) | Derivados de piperidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, una composicion farmaceutica que loscontiene y un procedimiento para obtener esta composicion farmaceutica | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| BR0311642A (pt) | Formulação de divalproex de sódio de liberação aumentada | |
| PE20021016A1 (es) | Conjugados de pregabalina-lactosa | |
| ES2156616T3 (es) | (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |